Drugs / XmAb2513
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00606645 | Dec 2007 → Apr 2010 | Hodgkins lymphoma, anaplastic large cell lymphoma | Xencor, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2009-06-01 | Xencor, Inc. | Results Xencor Presents Preliminary Phase 1 Data on XmAb®2513 Antibody for Lymphomas at 2009 American Society of Clinical Oncology Annual Meeting xencor.com ↗
Xencor, Inc., an antibody discovery and development company, today announced initial results from its Phase I study of XmAb®2513 in patients with relapsed Hodgkin lymphoma (HL). |
| 2007-12-10 | Xencor, Inc. | Results Xencor Data from Pre-clinical XmAb™ Antibody Studies Presented at American Society of Hematology Meeting xencor.com ↗
XmAb2513 provided statistically significant reductions in tumor growth and enhancement of survival, and was effective in eliminating established tumors in murine models of disease. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2009-06-01 | Xencor, Inc. | Xencor Presents Preliminary Phase 1 Data on XmAb®2513 Antibody for Lymphomas at 2009 American Society of Clinical Oncology Annual Meeting xencor.com ↗ |
| 2008-02-11 | Xencor, Inc. | Xencor Initiates Phase I Clinical Trial with XmAb2513 in Lymphoma xencor.com ↗ |
| 2007-12-10 | Xencor, Inc. | Xencor Data from Pre-clinical XmAb™ Antibody Studies Presented at American Society of Hematology Meeting xencor.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XmAb2513 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00606645 ↗ |
| Route | Intravenous | “Intravenous infusion of XmAb2513 administered at a dose of 0.3, 1.0, 3.0, 6.0, 9.0, or 12 mg/kg in sequential dose cohorts.” NCT00606645 ↗ |